Share ownership Jaguar Health, Inc.

JAGX

US47010C8881

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 02:30:00 11/02/2026 am IST			5-day change	1st Jan Change
0.6420 ^USD	-2.87%		+0.30%	-31.06%

16/01	Jaguar Health Inc - Co & unit entered license agreement with Woodward Specialty LLC - SEC filing	RE
06/01	Jaguar Health, Inc. announced that it has received $0.35 million in funding	CI

Share class: Jaguar Health, Inc.

	Vote	Quantity	Free-Float	Total Float
Stock A	0	99	0	81.66 %
Stock B	0	9	0
Stock C	1	1,30,88,288	1,06,87,254 ( 81.66 %)

Major shareholders: Jaguar Health, Inc.

Name	Equities	%	Valuation
Lincoln Alternative Strategies LLC 16.06 %	6,00,000	16.06 %	405 000 $
Joshua Mailman 15.72 %	5,87,320	15.72 %	396 441 $
Iliad Management Ltd. 11.78 %	4,40,000	11.78 %	297 000 $
Brown Stone Capital Ltd. 4.325 %	1,61,583	4.325 %	109 069 $
DRW Securities LLC 2.435 %	90,968	2.435 %	61 403 $
WBW Trust Number One 2.105 %	78,621	2.105 %	53 069 $
Intracoastal Capital LLC 1.74 %	65,002	1.74 %	43 876 $
Fredrick Waid 1.367 %	51,084	1.367 %	34 482 $
Jon D. & Linda W. Gruber Trust 1.151 %	43,000	1.151 %	29 025 $
Lisa Conte 0.7832 %	29,258	0.7832 %	19 749 $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Streeterville Management LLC 81.82 %	99	81.82 %	67 $
Iliad Management Ltd. 18.18 %	22	18.18 %	15 $

Name	Equities	%	Valuation
Iliad Management Ltd. 65.38 %	170	65.38 %	115 $
Streeterville Management LLC 34.62 %	90	34.62 %	61 $

Breakdown by shareholder type

Other	37.17%
Individuals	19.87%
Institutional	3.37%
Unknown	39.59%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	24.4%
Individuals	19.87%
Mauritius	11.78%
United Kingdom	4.33%
Canada	0.02%
Japan	0.01%
Switzerland	0.01%

Based on 1000 largest holdings

Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.

Employees

Sector

Pharmaceuticals

Calendar

06/04 - Q4 2025 Earnings Release (Projected)

More about the company